Search

Your search keyword '"Eichenauer, Dennis A."' showing total 48 results
Start Over Author "Eichenauer, Dennis A." Journal blood
48 results on '"Eichenauer, Dennis A."'

1. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Author

Albert, Annemarie, Bramstedt, Jörn, Brand, Marcus, Brinkkötter, Paul T., Cukoski, Sadrija, Eichenauer, Dennis A., Elitok, Saban, Felten, Helmut, Gäckler, Anja, Geuther, Gesa, Harth, Ana, Hausberg, Martin, Hermann, Matthias, Hinkel, Ulrich P., Jabs, Wolfram Johannes, Kaufeld, Jessica, Klein, Gilles, Klemm, Kristin, Kolbrink, Benedikt, Kühne, Lucas, Menne, Jan, Miesbach, Wolfgang, Mühlfeld, Anja Susanne, Özcan, Fedai, Osterholt, Thomas, Pfrepper, Christian, Potthoff, Sebastian A., Radermacher, Jörg, Ruhe, Johannes, Schmidt, Tilman, Schönermarck, Ulf, Schönfelder, Kristina, Schreiber, Adrian, Schulte, Kevin, Schulte-Kemna, Lena, Schwenger, Vedat, Seelow, Evelyn, Seibert, Felix S., Todorova, Polina, Tölle - Charité, Markus, Völker, Linus A., Walendy, Victor, Wendt, Ralph, Westhoff, Timm H., Knöbl, Paul, Eller, Kathrin, Thaler, Johannes, Sperr, Wolfgang R., Gleixner, Karoline, Buxhofer-Ausch, Veronika, Mühlfeld, Anja, Jabs, Wolfram J., Westhoff, Timm, and Brinkkoetter, Paul T.

Published
2024
Full Text
View/download PDF

3. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Author

Kühne, Lucas, Knöbl, Paul, Eller, Kathrin, Thaler, Johannes, Sperr, Wolfgang R., Gleixner, Karoline, Osterholt, Thomas, Kaufeld, Jessica, Menne, Jan, Buxhofer-Ausch, Veronika, Mühlfeld, Anja, Seelow, Evelyn, Schreiber, Adrian, Todorova, Polina, Cukoski, Sadrija, Jabs, Wolfram J., Özcan, Fedai, Gäckler, Anja, Schönfelder, Kristina, Seibert, Felix S., Westhoff, Timm, Schwenger, Vedat, Eichenauer, Dennis A., Völker, Linus A., Brinkkoetter, Paul T., Albert, Annemarie, Bramstedt, Jörn, Brand, Marcus, Brinkkötter, Paul T., Cukoski, Sadrija, Eichenauer, Dennis A., Elitok, Saban, Felten, Helmut, Gäckler, Anja, Geuther, Gesa, Harth, Ana, Hausberg, Martin, Hermann, Matthias, Hinkel, Ulrich P., Jabs, Wolfram Johannes, Kaufeld, Jessica, Klein, Gilles, Klemm, Kristin, Kolbrink, Benedikt, Kühne, Lucas, Menne, Jan, Miesbach, Wolfgang, Mühlfeld, Anja Susanne, Özcan, Fedai, Osterholt, Thomas, Pfrepper, Christian, Potthoff, Sebastian A., Radermacher, Jörg, Ruhe, Johannes, Schmidt, Tilman, Schönermarck, Ulf, Schönfelder, Kristina, Schreiber, Adrian, Schulte, Kevin, Schulte-Kemna, Lena, Schwenger, Vedat, Seelow, Evelyn, Seibert, Felix S., Todorova, Polina, Tölle - Charité, Markus, Völker, Linus A., Walendy, Victor, Wendt, Ralph, and Westhoff, Timm H.

Abstract

•Caplacizumab with immunosuppression, but without additional TPE, is an effective and safe treatment strategy for acute iTTP.

Published
2024
Full Text
View/download PDF

8. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Author

Hartmann, Sylvia, Eichenauer, Dennis A., Plütschow, Annette, Mottok, Anja, Bob, Roshanak, Koch, Karoline, Bernd, Heinz-Wolfram, Cogliatti, Sergio, Hummel, Michael, Feller, Alfred C., Ott, German, Möller, Peter, Rosenwald, Andreas, Stein, Harald, Hansmann, Martin-Leo, Engert, Andreas, and Klapper, Wolfram

Published
2013
Full Text
View/download PDF

10. Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Author

Kühne, Lucas, primary, Eichenauer, Dennis A., additional, Knöbl, Paul, additional, Völker, Linus A., additional, Kaufeld, Jessica, additional, Wendt, Ralph, additional, Hägele, Holger, additional, Osterholt, Thomas, additional, Bieringer, Marcus, additional, Buxhofer-Ausch, Veronika, additional, Menne, Jan, additional, Schoenermarck, Ulf, additional, and Brinkkoetter, Paul, additional

Published
2021
Full Text
View/download PDF

11. PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Author

Fuchs, Michael, primary, Jacob, Anne Sophie, additional, Kaul, Helen, additional, Kobe, Carsten, additional, Pabst, Thomas, additional, Greil, Richard, additional, Eichenauer, Dennis A., additional, Topp, Max, additional, Just, Marianne, additional, Hertenstein, Bernd, additional, Schaub, Valdete, additional, Vogelhuber, Martin, additional, Zijlstra, Josée M, additional, Plütschow, Annette, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2021
Full Text
View/download PDF

13. Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Author

Heger, Jan-Michel, primary, Graef, Claus Moritz, additional, Falderbaum, Philipp, additional, Gödel, Philipp, additional, Balke-Want, Hyatt, additional, Simon, Florian, additional, Sieg, Noëlle, additional, Naendrup, Jan-Hendrik, additional, Neumann, Marie Anne-Catherine, additional, Gillessen, Sarah, additional, Bröckelmann, Paul J, additional, Eichenauer, Dennis A., additional, Borchmann, Peter, additional, and Von Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

14. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Author

Gillessen, Sarah, primary, Plütschow, Annette, primary, Fuchs, Michael, primary, Markova, Jana, primary, Greil, Richard, primary, Topp, Max S., primary, Meissner, Julia, primary, Zijlstra, Josée M, primary, Eichenauer, Dennis A., primary, Diehl, Volker, primary, Borchmann, Peter, primary, Engert, Andreas, primary, and von Tresckow, Bastian, primary

Published
2019
Full Text
View/download PDF

17. Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Author

von Tresckow, Bastian, primary, Hüttmann, Andreas, additional, Vucinic, Vladan, additional, Mueller, Horst, additional, Plütschow, Annette, additional, Viardot, Andreas, additional, Topp, Max S., additional, Kobe, Carsten, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Haverkamp, Heinz, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2018
Full Text
View/download PDF

18. Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Author

Borchmann, Peter, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Lohri, Andreas, additional, Greil, Richard, additional, Eichenauer, Dennis A., additional, Zijlstra, Josée M, additional, Markova, Jana, additional, Meissner, Julia, additional, Feuring-Buske, Michaela, additional, Hüttmann, Andreas, additional, Dierlamm, Judith, additional, Sökler, Martin, additional, Krause, Stefan W., additional, Eich, Hans, additional, Baues, Christian, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Dietlein, Markus, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

21. Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Author

Borchmann, Peter, primary, Eichenauer, Dennis A., additional, Pluetschow, Annette, additional, Haverkamp, Heinz, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Soekler, Martin, additional, Hellmuth, Johannes C., additional, Meissner, Julia, additional, Mathas, Stephan, additional, Behringer, Karolin, additional, Dietlein, Markus, additional, Kobe, Carsten, additional, Diehl, Volker, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

22. Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Goergen, Helen, additional, Pluetschow, Annette, additional, Behringer, Karolin, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul, additional, Fuchs, Michael, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

24. A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Author

von Tresckow, Bastian, primary, Pluetschow, Annette, additional, Haverkamp, Heinz, additional, Vucinic, Vladan, additional, Rank, Andreas, additional, Topp, Max S., additional, Feuring-Buske, Michaela, additional, Kobe, Carsten, additional, Kuhnert, Georg, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2014
Full Text
View/download PDF

26. Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Author

Rothe, Achim, primary, Sasse, Stephanie, additional, Topp, Max S., additional, Eichenauer, Dennis A., additional, von Tresckow, Bastian, additional, Hummel, Horst-Dieter, additional, Ravic, Miroslav, additional, Marschner, Jens-Peter, additional, and Engert, Andreas, additional

Published
2014
Full Text
View/download PDF

27. Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Author

Böll, Boris, primary, Behringer, Karolin, additional, Görgen, Helen, additional, Bröckelmann, Paul, additional, von Tresckow, Bastian, additional, Eichenauer, Dennis A., additional, Fuchs, Michael, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2014
Full Text
View/download PDF

28. German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Author

Böll, Boris, primary, Plütschow, Annette, additional, Fuchs, Michael, additional, Eichenauer, Dennis A., additional, Thielen, Indra, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Atta, Johannes, additional, Pfreundschuh, Michael, additional, Feuring-Buske, Michaela, additional, Vogelhuber, Martin, additional, Sökler, Martin, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2013
Full Text
View/download PDF

29. A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Author

Zhukovsky, Eugene, primary, Rothe, Achim, additional, von Tresckow, Bastian, additional, Topp, Max, additional, Younes, Anas, additional, Eichenauer, Dennis A., additional, Hummel, Horst, additional, Reiners, Katrin S., additional, Dietlein, Markus, additional, Kessler, Joerg, additional, Ravic, Miroslav, additional, Hucke, Christian, additional, Strandmann, Elke Poggevon, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

30. Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Author

von Tresckow, Bastian, primary, Haverkamp, Heinz, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

31. A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Author

von Tresckow, Bastian, primary, Skotnicki, Aleksander, additional, Lisukov, Igur, additional, Srivastava, Shivani, additional, Morgan, David S., additional, Morschhauser, Franck, additional, Stelitano, Caterina, additional, Szer, Jeffrey, additional, Eichenauer, Dennis A., additional, Abramson, Jeremy S., additional, Sureda, Anna, additional, Ferme, Christophe, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

32. Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Author

Borchmann, Peter, primary, Eichenauer, Dennis A., additional, Plütschow, Annette, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Soekler, Martin, additional, Engel, Nicole, additional, Meissner, Julia, additional, Mathas, Stephan, additional, Behringer, Karolin, additional, Dietlein, Markus, additional, Kobe, Carsten, additional, Diehl, Volker, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

34. Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Author

Tresckow, Bastian von, primary, Görgen, Helen, additional, Plütschow, Annette, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Rothe, Achim, additional, Fuchs, Michael, additional, Behringer, Karolin, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2013
Full Text
View/download PDF

36. Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Author

Rancea, Michaela, primary, Engert, Andreas, additional, Borchmann, Peter, additional, von Tresckow, Bastian, additional, Halbsguth, Teresa, additional, Behringer, Karolin, additional, Wongso, Diana, additional, Böll, Boris, additional, Klimm, Beate, additional, Thielen, Indra, additional, Eichenauer, Dennis A., additional, and Skoetz, Nicole, additional

Published
2012
Full Text
View/download PDF

37. Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Author

von Tresckow, Bastian, primary, Müller, Horst, additional, Eichenauer, Dennis A., additional, Glossmann, Jan Peter, additional, Josting, Andreas, additional, Böll, Boris, additional, Klimm, Beate, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2012
Full Text
View/download PDF

38. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Author

Böll, Boris, primary, Bredenfeld, Henning, additional, Görgen, Helen, additional, Halbsguth, Teresa, additional, Eich, Hans T., additional, Soekler, Martin, additional, Markova, Jana, additional, Keller, Ulrich, additional, Graeven, Ullrich, additional, Kremers, Stephan, additional, Geissler, Michael, additional, Trenn, Guido, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Eichenauer, Dennis A., additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2011
Full Text
View/download PDF

40. A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Author

Rothe, Achim, primary, Younes, Anas, additional, Reiners, Katrin S., additional, Dietlein, Markus, additional, Eichenauer, Dennis A., additional, Kessler, Joerg, additional, Topp, Max S., additional, Hummel, Horst, additional, Ravic, Miroslav, additional, Hucke, Christian, additional, von Strandmann, Elke Pogge, additional, and Engert, Andreas, additional

Published
2011
Full Text
View/download PDF

42. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Fuchs, Michael, additional, Pluetschow, Annette, additional, Klimm, Beate, additional, Halbsguth, Teresa, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Nogová, Lucia, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2011
Full Text
View/download PDF

44. Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Author

Eichenauer, Dennis A., primary, Bredenfeld, Henning, additional, Franklin, Jeremy, additional, Haverkamp, Heinz, additional, Mueller, Horst, additional, Eich, Hans T., additional, Mueller, Rolf-Peter, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Diehl, Volker, additional, and Engert, Andreas, additional

Published
2009
Full Text
View/download PDF

45. Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial

Author

von Tresckow, Bastian, primary, Peine, Denissa, additional, Böll, Boris, additional, Eichenauer, Dennis A, additional, von Strandmann, Elke Pogge, additional, Knop, Stefan, additional, Goebeler, Marielle, additional, Hallek, Michael, additional, Engert, Andreas, additional, and Hübel, Kai, additional

Published
2008
Full Text
View/download PDF

46. The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Author

Mueller, Horst, primary, Nogova, Lucia, primary, Eichenauer, Dennis A, primary, Halbsguth, Teresa, primary, Nisters-Backes, Hiltrud, primary, Schober, Thomas, primary, Eimermacher, Hartmut, primary, Borchmann, Peter, primary, Fuchs, Michael, primary, Engert, Andreas, primary, and Josting, Andreas, primary

Published
2008
Full Text
View/download PDF

47. Brentuximab vedotin for relapsed or refractory CD30+hematologic malignancies: the German Hodgkin Study Group experience

Author

Rothe, Achim, Sasse, Stephanie, Goergen, Helen, Eichenauer, Dennis A., Lohri, Andreas, Jäger, Ulrich, Bangard, Christopher, Böll, Boris, von Bergwelt Baildon, Michael, Theurich, Sebastian, Borchmann, Peter, and Engert, Andreas

Abstract

The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration. In the present study, we report the experience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with refractory or relapsed CD30+Hodgkin lymphoma who were treated either in a named patient program (n = 34) or in the context of a safety study associated with the registration program of this drug. In these very heavily pretreated patients, an objective response rate of 60%, including 22% complete remissions, could be documented. The median duration of response was 8 months. This retrospective analysis supports the previously reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30+malignancies. This trial was registered at www.clinicaltrials.govwith identifier NCT01026233.

Published
2012
Full Text
View/download PDF

48. phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Author

Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, von Strandmann, Elke Pogge, Borchmann, Peter, and Engert, Andreas

Subjects
*BISPECIFIC antibodies, *CD30 antigen, *KILLER cells, *HODGKIN'S disease treatment, *DISEASE relapse
Abstract

AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via binding to CD16A as immune effector cells. In this phase 1 dose-escalation study, 28 patients with heavily pretreated relapsed or refractory Hodgkin lymphoma received AFM13 at doses of 0.01 to 7 mg/kg body weight. Primary objectives were safety and tolerability. Secondary objectives included pharmacokinetics, antitumor activity, and pharmacodynamics. Adverse events were generally mild to moderate. The maximum tolerated dose was not reached. Pharmacokinetics assessment revealed a half-life of up to 19 hours. Three of 26 evaluable patients achieved partial remission (11.5%) and 13 patients achieved stable disease (50%), with an overall disease control rate of 61.5%. AFM13 was also active in brentuximab vedotin-refractory patients. In 13 patients who received doses of ≥1.5 mg/kg AFM13, the overall response rate was 23% and the disease control rate was 77%. AFM13 treatment resulted in a significant NK-cell activation and a decrease of soluble CD30 in peripheral blood. In conclusion, AFM13 represents a welltolerated, safe, and active targeted immunotherapy of Hodgkin lymphoma. A phase 2 study is currently planned to optimize the dosing schedule in order to further improve the therapeutic efficacy. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results